506072550 05/22/2020

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6119265

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
CEDRIC FRANCOIS	03/03/2020
PASCAL DESCHATELETS	03/05/2020

### **RECEIVING PARTY DATA**

Name:	APELLIS PHARMACEUTICALS, INC.
Street Address:	6400 WESTWIND WAY
Internal Address:	SUITE A
City:	CRESTWOOD
State/Country:	KENTUCKY
Postal Code:	40014

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16030541

### CORRESPONDENCE DATA

Fax Number: (617)502-5002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6172485000

Email: patentdocket@choate.com

**CHOATE HALL & STEWART LLP Correspondent Name:** Address Line 1: TWO INTERNATIONAL PLACE

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	2008575-0289
NAME OF SUBMITTER:	MELISSA M. ADAMS, PHD
SIGNATURE:	/Melissa M. Adams/
DATE SIGNED:	05/22/2020
	This document serves as an Oath/Declaration (37 CFR 1.63).

#### **Total Attachments: 7**

source=2008575-0289 Combined Joint Assignement & Declaration#page1.tif source=2008575-0289 Combined Joint Assignement & Declaration#page2.tif source=2008575-0289 Combined Joint Assignement & Declaration#page3.tif

source=2008575-0289 Combined Joint Assignement & Declaration#page4.tif source=2008575-0289 Combined Joint Assignement & Declaration#page5.tif source=2008575-0289 Combined Joint Assignement & Declaration#page6.tif source=2008575-0289 Combined Joint Assignement & Declaration#page7.tif

Docket Number: 2008575-0289

# **COMBINED JOINT ASSIGNMENT & DECLARATION**

### A. ASSIGNMENT

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
	Prospect, Kentucky
2. Pascal Deschatelets	Prospect, Kentucky

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

### COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN; and

prep	pared for filing in the United S	States Patent and Tra	ademark Office; or	
x iden	tified by United States Appli	cation No.	16/030,541	
filed in the Uni	ted States Patent and Tradem	ark Office on	July 9, 2018	; and
iden	tified by International Patent	Application No; and		
x and	is also aware of the following	g priority application	ıs:	
	Application No.	· ]	Filed	
	15/209665	July	13, 2016	

WHEREAS, Apellis Pharmaceuticals, Inc. (hereinafter "ASSIGNEE"), having a usual place of business at 6400 Westwind Way, Suite A, Crestwood, Kentucky 40014, desires to acquire or confirm an interest therein:

April 10, 2013

June 22, 2011 June 22, 2010

13/805538

PCT/US11/41492

61/357448

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout

8745828v1

Page 1 of 7

the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct application number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said

2008575-0289

application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

8745828v1 Page 3 of 7 2008575-0289

# B. <u>DECLARATION (37 CFR 1.63)</u>

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

## COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN; and

attached hereto or prepared for filing in the United Office; or	States Patent and Tra	demark
x identified by United States Application No.	16/030,541	
filed in the United States Patent and Trademark Office on	July 9, 2018	; oı
identified by International Patent Application No.		

The above-identified application was made or authorized to be made by us.

We believe that we are each an original joint inventor of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

2008575-0289

Signature: Cedric Francois	Date: 3/3/2020
Witness Signature Lello Witness Name (printed): Laron Zullo	
Witness Signature: Witness Name (printed): Cin Johnson	

Signature:  Proved Posselectelets	Date: MAR 05,
Pascal Deschatelets	
Witness Signature: Lel Ole	
Witness Name (printed): Koren Zeello	
Witness Signature: CLUMD M	
Witness Name (printed):	

The undersigned (whose title is supplied below) is authorized to act on behalf of Apellis			
Pharmaceuticals, life.			
Signature:	Date:	3/2/2000	
Name (printed): DAVID WATSOW	_		
Title (printed): 5£CRETARY	_		

8745828v1

**RECORDED: 05/22/2020** 

Page 7 of 7

2008575-0289